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Abstract. Malignant pleural mesothelioma (MPM) is a rare 
aggressive cancer of the pleura. Asbestos exposure (through 
inhalation) is the most well established risk factor for meso-
thelioma. The current standard of care for patients suffering 
from MPM is a combination of cisplatin and pemetrexed (or 
alternatively cisplatin and raltitrexed). Most patients, however, 
die within 24 months of diagnosis. New therapies are therefore 
urgently required for this disease. Lysine acetyltransferases 
(KATs) including KAT5 have been linked with the develop-
ment of cisplatin resistance. This gene may therefore be 
altered in MPM and could represent a novel candidate target 
for intervention. Using RT-PCR screening the expression of all 
known KAT5 variants was found to be markedly increased in 
malignant tumors compared to benign pleura. When separated 
according to histological subtype, KAT5 was significantly 
overexpressed in both the sarcomatoid and biphasic subgroups 
for all transcript variants. A panel of MPM cell lines including 
the normal pleural cells LP9 and Met5A was screened for 
expression of KAT5 variants. Treatment of cells with a small 
molecule inhibitor of KAT5 (MG-149) caused significant 
inhibition of cellular proliferation (P<0.0001), induction of 
apoptosis and was accompanied by significant induction of 
pro-inflammatory cytokines/chemokines.
Introduction
Malignant pleural mesothelioma (MPM) is an aggressive 
inflammatory cancer, predominantly arising from prior expo-
sure to asbestos (1). An extended lag period between exposure 
and disease onset coupled with the non-descript nature of the 
symptoms associated with this disease means that the vast 
majority of patients when diagnosed present at an advanced 
stage. Overall survival for MPM is poor with most patients 
dying within one year of diagnosis (2,3). A conservative 
estimate has suggested that globally ~43,000 people die from 
this disease annually, but the actual number is probably much 
greater (4,5). Although there has been some recent advances in 
this disease, current standard of care is a combination of peme-
trexed and cisplatin chemotherapy (6), which is non-curative 
and results in a response rate of ~40% (7). Consequently, there 
is an urgent need to identify novel therapeutic avenues in this 
disease to improve patient outcomes.
Epigenetics is often described as ‘chromatin-based events 
that regulate DNA-templated processes’ (8). Furthermore, it 
is also now well established that aberrant epigenetics are a 
common feature in cancer, including mesothelioma (9).
Epigenetic regulation of chromatin is often described as 
a code (10) involving regulatory proteins that act as ‘readers’, 
‘writers’ or ‘erasers’ of this code. The majority of these 
proteins utilize various post-translational modifications such 
as histone acetylation on core histones to elicit responses (11). 
The enzymes which write/erase histone acetylation are called 
lysine acetyltransferases (KATs) and histone deacetylases 
(HDACs), respectively (12). Since their discovery, significant 
effort has been expended by the pharmaceutical sector to 
develop agents that target these proteins. One such compound, 
vorinostat, is a histone deacetylase inhibitor FDA approved for 
the treatment of cutaneous T-cell lymphoma (13), was tested 
in a phase III clinical trial as a second or third-line treatment 
in MPM, but unfortunately did not improve overall survival 
and cannot be recommended as a therapy for patients with 
MPM (14).
Lysine acetyltransferases are also emerging as candidate 
therapeutic targets in cancer with the recent development 
of several inhibitors targeting these proteins (15,16). There 
are, however, a significant number of KATs and the KAT 
KAT5 (Tip60) is a potential therapeutic target 
in malignant pleural mesothelioma
SIAN CREGAN1-3,  LAURAN McDONAGH4,  YUN GAO1,5,  MARTIN P. BARR1,4, 
KENNETH J. O'BYRNE1,6,  STEPHEN P. FINN7,  SINEAD CUFFE8  and  STEVEN G. GRAY1,4
1Thoracic Oncology Research Group, Institute of Molecular Medicine, St. James's Hospital, Dublin; 
2Department of Surgery, 3MSc in Translational Oncology Program, and 4Department of Clinical Medicine, 
Trinity College Dublin, Dublin, Ireland; 5Department of Oncology, Aerospace Central Clinical Medical 
College of Peking University, Beijing, P.R. China; 6Cancer and Ageing Research Program, Queensland 
University of Technology, Brisbane, Australia; 7Department of Histopathology and Morbid Anatomy, 
Trinity College Dublin, Dublin; 8HOPE Directorate, St. James's Hospital, Dublin, Ireland
Received November 3, 2015;  Accepted December 16, 2015
DOI: 10.3892/ijo.2016.3335
Correspondence to: Dr Steven G. Gray, Thoracic Oncology 
Research Group, Room 1.06, Trinity Centre for Health Sciences, 
Institute of Molecular Medicine, St. James's Hospital, Dublin 8, 
Ireland
E-mail: sgray@stjames.ie
Key words: mesothelioma, lysine acetyltransferase, epigenetics, 
MG 149, inflammation
CREGAN et al:  KAT5 IS A POTENTIAL THERAPEUTIC TARGET IN MPM2
superfamily itself can be separated into several subfami-
lies (17). One of these is the MYST family comprising 
KAT5-KAT8 (18). MYST KATs have diverse functions 
affecting the majority of cellular processes, ranging from gene 
regulation, cell cycle, stem cell homeostasis and development 
and critically DNA damage repair (18). A member of the 
MYST family, KAT5 (also known as Tip60) is the catalytic 
subunit of the NuA4 histone acetyltransferase complex which 
is involved in transcriptional activation of select genes. This 
complex may be required for the activation of transcriptional 
programs associated with oncogene and proto-oncogene 
mediated growth induction, tumor suppressor mediated 
growth arrest and replicative senescence, apoptosis and DNA 
repair (19,20). Critically, KAT5 has now also been linked 
to: i) activation of excision repair cross-complementation 
group 1 (ERCC1) a critical DNA damage repair protein in 
response to exposure to cisplatin (21); and ii) with the devel-
opment of cisplatin resistance (22). As such, given that the 
standard first-line therapy for MPM is cisplatin based (6), 
we examined whether the expression of KAT5 is altered in 
MPM and if this protein could represent a novel candidate 
target for intervention in this disease. Our results show that 
KAT5 is significantly elevated in MPM, and targeting this 
protein with small molecule inhibitors results in insignificant 
anti-proliferative and apoptotic responses in MPM cell lines, 
further underlining the therapeutic potential of targeting this 
protein in mesothelioma.
Materials and methods
Primary tumor samples. Surgical specimens were obtained 
as discarded tumor samples from patients who had under-
gone extended pleuro-pneumonectomy at Glenfield Hospital 
(Leicester, UK). Benign specimens were acquired from 
patients never diagnosed with MPM. Informed consent was 
obtained from each patient, and the study was conducted after 
formal approval from the relevant Hospital Ethics Committee. 
Samples consisted of the following: 5 benign lesions and 17 
MPM samples (epithelioid, n=7; biphasic, n=6; and sarcoma-
toid, n=4).
Cell culture. All MPM cell lines were maintained in a 
humidified atmosphere containing 5% CO2 in appropriate 
media supplemented with 10% fetal bovine serum (FBS) 
and penicillin streptomycin (500 U/ml). Cell culture reagents 
were purchased from Lonza (Walkersville, MD, USA). 
Twenty-four MPM cell lines were used in the study: LP9, 
Met5A, NCI-H2596, MMP, MMB, NCI-H2052, NCI-H28, 
Ju77, One58, RS-5, DM-3, ACC-MESO-1, ACC-MESO-4, 
Y-MESO-8D, Y-MESO-9, Y-MESO-12, Y-MESO-14, M14K, 
M24K, M25K, M28K, M33K, M38K and LO68.
LP9, MMP and MMB were a generous gift from Dr Warren 
Thomas (Royal College of Surgeons in Ireland, Dublin, 
Ireland). ACC-MESO-1, ACC-MESO-4, Y-MESO-8D, 
Y-MESO-9, Y-MESO-12 and Y-MESO-14 were generously 
provided by Yoshitaka Sekido (Aichi Cancer Center Research 
Institute, Nagoya, Japan). NCI-H2052, One58 and JU77 cells 
were provided by Duncan Stewart (University of Leicester, 
Leicester, UK). The NCI-H2596 and REN cell lines were 
kindly provided by Dean Fennell (Queen's University, Belfast, 
Northern Ireland). M14K, M24K, M25K, M28K, M33K and 
M38K were generously provided by Dr Hannu Norppa (Finnish 
Institute of Occupational Health, Helsinki, Finland). NCI-H28, 
and the immortalized non-tumorigenic mesothelial cell line, 
Met-5A were purchased from the ATCC (LGC Promochem, 
Teddington, UK). RS-5 and DM-3 were purchased from 
the DSMZ (Leibniz Institute DSMZ-German Collection of 
Microorganisms and Cell Cultures, Braunschweig, Germany).
Reagents. MG 149 (23) was purchased from Axon Medchem 
BV (Groningen, The Netherlands), and dissolved in dimethyl 
sulfoxide (DMSO). Cells were serum starved (0.5% FBS) for 
24 h prior to the addition of drugs.
Proliferation assay. Cell proliferation was measured using a 
Cell Proliferation BrdU ELISA (Roche Diagnostics Ltd., West 
Sussex, UK), according to manufacturer's instructions. Briefly, 
cells (REN or H26) were seeded at 3x103/well in a 96-well 
plate. Following overnight incubation, cells were treated for 
24 h with MG 149 at 1, 5, 10, 15, 20 and 25 µM. Absorbance 
was measured on a plate reader at 450 nm with a reference 
wavelength set to 690 nm. Untreated wells were used for 
normalization purposes and set to 100%.
Cellular apoptosis (FACS). NCI-H226 cells were seeded in 
6-well plates at a density of 1x105 cells/well and were allowed 
to adhere overnight. Subsequently the complete media was 
removed and the cells washed with 100 ml PBS. Serum 
depleted media (0.5% FBS) was added and the cells incubated 
for a further 24 h, then treated with appropriate concentrations 
of drug, diluted in cell culture media, for a further 48 h. Where 
appropriate, control cells were treated with either vehicle or 
left untreated with media only. Following treatment, culture 
media was removed, transferred to labeled FACS tubes and 
placed on ice. Adhered cells were then trypsinised and trans-
ferred to corresponding FACS tubes. Cells were pelleted by 
centrifugation at 1,300 rpm for 3 min and the supernatant 
removed. The cells were washed in 1 ml of 1X binding buffer 
(BB) diluted in ice cold PBS, pelleted by centrifugation and 
resuspended in 100 µl BB. Annexin V (2 µl) (IQ Products, 
Groningen, The Netherlands) was added to each tube, with 
the exception of the negative control and media only samples, 
and cells were incubated at 4˚C for 20 min, protected from 
light. Cells were again washed in 1 ml 1X binding buffer and 
supernatant removed. Immediately before analysis by flow 
cytometry, cells were resuspended in 400 µl BB containing 
0.5 µg/ml PI (Invitrogen, Paisley, UK), except the negative 
control and FMO (fluorescence minus one) control for PI for 
which BB alone was used.
Caspase-3/7 activation. Activation of caspase-3/7 was 
measured using a FluoroFire Caspase-3/7 fluorescent assay 
kit according to the manufacturer's instructions (Molecutools, 
Dublin, Ireland). NCI-H226 cells were seeded in 96-well plates 
at a density of 4x103 cells/well and were allowed to adhere 
overnight. Subsequently the complete media was removed 
and the cells washed with 100 ml PBS. Serum depleted media 
(0.5% FBS) was added and the cells incubated for a further 
24 h, then treated with appropriate concentrations of drug, 
diluted in cell culture media, for a further 48 h.
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RNA isolation and RT-PCR amplification. Total RNA was 
extracted using TRI reagent® (Molecular Research Center, 
Cincinnati, OH, USA) according to manufacturer's instructions. 
Prior to First Strand cDNA Synthesis, 250 ng (primary tumors) 
or 500 ng (cell lines) total RNA was pre-treated by digestion 
with Amplification grade DNase I (Sigma-Aldrich, St. Louis, 
MO, USA) according to the manufacturer's instructions. 
cDNA was subsequently generated using All-in-One cDNA 
Synthesis SuperMix (Biotool, Houston, TX, USA) according 
to the manufacturer's instructions. Cell lines were examined 
for the expression of KAT5 variants (RefSeq NM_182710.2, 
NM_006388.3, NM_182709.2 and NM_001206833.1) and 
18s rRNA by RT-PCR, using the following primers, or as 
previously published (24). KAT5v1, 5'-atggcggaggtggtgagtc-3; 
KAT5v2, 5'-gcggaggtgggggagataat-3'; and KAT5R, 5'-gaaac 
cacctccaccttccg-3'.
Amplification with KAT5v1 and KAT5R recognizes vari-
ants 1 and 4, while amplification with KAT5v2 and KAT5R 
will amplify variants 2 and 3.
PCR cycling conditions were 95˚C for 5 min followed by 
35 cycles of 1 min at 95˚C, 1 min at 58˚C, 1 min at 72˚C, for 
35 cycles, with a final extension of 72˚C for 10 min. A total of 
8 µl of the experimental RT-PCR product and 2 µl of the 18s 
rRNA RT-PCR product was loaded and run on 2% agarose 
gel. Following image capture, product quantification was 
performed using TINA 2.09c (Raytest, Isotopenmeßgeräte 
GmbH, Straubenhardt, Germany) densitometry software. The 
mRNA expression was normalized to the loading control (18s 
rRNA), and was expressed as a ratio of target mRNA expres-
sion: loading control expression.
Analysis of mRNA expression by RT-qPCR. Validation 
of RT-PCR results was subsequently confirmed using 
SYBR-Green based quantitative real-time PCR (RT-qPCR). 
RT-qPCR reactions were carried out for CXCL8 using previ-
ously published primers (24). Primers used to analyze CXCL1, 
and CXCL13 were purchased from Real Time Primers, LLC 
(Elkins Park, PA, USA).
RT-qPCRs were conducted on an Illumina Eco qPCR 
using GoTaq® qPCR Master Mix (Promega) using a 2-step 
qPCR program with the following cycling parameters as 
recommended by Real Time Primers: An initial polymerase 
activation of 95˚C for 2 min followed by 50 cycles of 95˚C 
for 10 sec and annealing/amplification at 58˚C for 45 sec. A 
melting curve analysis was conducted at the end of each PCR 
using 95˚C for 15 sec, 55˚C for 15 sec and a final 95˚C for 
15 sec. Data were analysed using the default in-built ΔΔCq 
analysis settings for relative quantification in Eco software.
Statistical analysis. All data are expressed as mean ± SEM 
unless stated otherwise. Statistical analysis was performed 
with GraphPad Prism v5.01 (GraphPad Software, La Jolla, 
Figure 1. Expression KAT5 variants in primary malignant pleural mesothelioma vs. benign pleura. (A) RT-PCR showing the expression of the various KAT5 
variants and 18s rRNA in a series of benign pleura and malignant tumors. (B) Densitometric analysis of RT-PCR products comparing tumor vs. benign. 
(C) Stratification according to histological subtype.
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CA, USA) using either unpaired two-tailed Student's t-test or 
Mann-Whitney Student's t-test. One-way analysis of variance 
(ANOVA) was used where groups in the experiment were 
three or more. Following ANOVA, post-test analyses utilized 
either the Tukey multiple comparisons test, or the Dunnett's 
multiple comparison tests.
Results
Expression of KAT5 in primary mesothelioma specimens. 
To assess the expression of KAT5 in a panel of fresh-frozen 
mesothelioma samples with a cohort of benign pleura RT-PCR 
was performed (Fig. 1A). KAT5 has four known RefSeq vari-
ants, and primers were designed to distinguish between all 
four variants. Densitometric analysis of the RT-PCR products 
revealed significantly increased expression of all four variants 
in primary MPM tumor samples compared with normal pleura 
(Fig. 1B). When stratified according to histological subtype, 
the most predominant upregulation was observed in the 
biphasic subtype (Fig. 1C).
Expression of KAT5 in a panel of normal and malignant 
mesothelial cell lines. Utilizing RT-PCR, the expression of 
KAT5 was examined in a panel of normal and malignant meso-
thelioma cell lines (Fig. 2A). All cell lines tested expressed 
varying levels of KAT5, with higher basal expression observed 
predominantly in the mesothelioma lines, whereas low basal 
levels of KAT5 were observed in the normal peritoneal meso-
thelial cell line LP9 (Fig. 2A).
Inhibition of KAT5 leads to reduced cellular proliferation. 
A small molecule inhibitor of KAT5 (MG 149) has been 
developed (23). The effect of this compound was subsequently 
tested on two cell lines (REN and NCI-H226). At concentra-
tions >10 µM, MG 149 was found to significantly reduce the 
proliferative rate of both MPM cell types (Fig. 2B).
Inhibition of KAT5 leads to increased cellular apoptosis. 
As cellular proliferation and viability were affected by treat-
ments with MG 149 we subsequently examined the effects of 
this compound with respect to cellular apoptosis. Using an 
Annexin V/FITC based FACs assay, 2.5 or 5 µM of MG 149 
was found to significantly increase cellular apoptosis at both 
24 and 48 h following treatment (Fig. 3A), and was associated 
with increased caspase-3/7 activation (Fig. 3B).
MG 149 treatments induce pro-inflammatory cytokine expres-
sion. Given the effects of MG 149 on cellular proliferation 
and apoptosis, and the fact that it targets an epigenetic regula-
tory protein, we then examined the effects of MG 149 on the 
expression of members of the CXC (ELR+) family namely 
CXCL1-3/GROα-γ, CXCL8/IL-8 and CXCL13. These are pro-
inflammatory chemokines, which we have previously shown to 
be epigenetically regulated in non-small cell lung cancer (24), 
and for which some have also been shown to be responsive to 
asbestos exposure (25). When cells were treated with MG 149 
(15 µM for 24 h), RT-PCR analysis showed significant induc-
tion/upregulation of four of the chemokines examined (Fig. 4A). 
Subsequently, using quantitative PCR (qPCR), we confirmed 
and validated the upregulation of CXCL1 and CXCL8, with a 
small yet significant downregulation of CXCL13 (Fig. 4B).
Discussion
In the UK, it is estimated that 91,000 deaths from mesothe-
lioma are predicted to occur from 1968 to 2050 with around 
Figure 2. Effects of MG 149 on cellular proliferation in MPM cell lines. (A) RT-PCR showing the expression of the various KAT5A variants in a panel of 
normal and malignant MPM cell lines. 18s rRNA was included as the loading control. (B) Effects of the MG 149 on cellular proliferation in NCI-H226 or REN 
cell lines as measured using a BrdU assay. Significance was measured using one-way analysis of variance (ANOVA) with a Dunnett's multiple comparison 
post-test with all samples compared against the DMSO control. 
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Figure 3. MG 149 induces apoptosis in MPM. (A) Induction of apoptosis by MG 149 in NCI-H226 cells as measured using Annexin V/PI FACs analysis. 
(B) Induction of caspase-3/7 by MG 149 in NCI-H226 cells. Statistical significance. *P<0.05; **P<0.01; ***P<0.001.
Figure 4. MG 149 alters expression of pro-inflammatory cytokines/chemokines (A) RT-PCR analysis demonstrating the induction of CXCL1, CXCL2, CXCL3 
and CXCL8 in cells treated with MG 149. (B) SYBR-Green relative quantification (RT-qPCR) analysis of CXCL1, CXCL8/IL-8 and CXCL13 expression 
changes in response to treatment with MG 149. Statistical significance was assessed using a paired two-tailed Student's t-test.
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61,000 of these occurring from 2007 onwards (26). The 
prevailing first-line chemotherapy regimen for mesothelioma 
remains cisplatin/pemetrexed (or cisplatin/raltitrexed) (6). 
Critically, only ~40% of patients respond to this regimen, and 
we therefore need to identify new agents for the treatment of 
this cancer.
KAT5 is a member of the lysine acetyltransferases, a large 
superfamily of epigenetic regulatory proteins which play a 
number of important cellular roles, and which are emerging as 
candidate targets for cancer therapy (15). In this regard, KAT5 
has been shown to be associated with resistance to cisplatin 
based therapy in the lung cancer setting (21,22), suggesting 
that its expression could also be important in mesothelioma 
cancer. We therefore examined the levels of this lysine 
acetyltransferase in a panel of primary tumors compared to 
benign pleura. Our results clearly demonstrated that expres-
sion of KAT5 mRNA was significantly elevated in the tumors 
compared to normal pleura (Fig. 1), and was ubiquitously 
expressed in a panel of mesothelioma cell lines (Fig. 2). In 
agreement with our data from primary tumors the expression 
of KAT5 was less highly expressed in the normal LP9 cell line 
compared to MPM cancer cell lines (Fig. 2), suggesting that 
KAT5 may be a potential therapeutic target in mesothelioma.
Several KAT5 specific inhibitors have been developed 
including MG 149 (23), TH1834 (27), Nu9056 (28) and various 
H3-CoA inhibitors (29). We exposed MPM cells to one of these 
inhibitors, MG 149, and demonstrated that KAT5 inhibition 
resulted in both significant anti-proliferative effects (Fig. 2B) 
and the induction of cellular apoptosis (Fig. 3) in cells.
Epigenetic therapies have had mixed results within the 
clinical setting particularly for agents such as histone deacety-
lase inhibitors (HDACi) when used as a monotherapy (30). 
Prior to 2013, estimates suggest that 490 clinical trials had 
been conducted with HDACi with very limited success (31), 
and indeed one of the most conspicuous failures for an 
HDACi was the VANTAGE-014 trial in mesothelioma, which 
examined the effect of vorinostat in patients with advanced 
malignant pleural mesothelioma who had progressed on 
previous chemotherapy (14). Nevertheless, epigenetic therapies 
remain attractive targets for the treatment of cancer, and recent 
‘breakthrough therapy FDA designation’ for entinostat for 
breast cancer when added to exemestane in postmenopausal 
women with ER+ metastatic breast cancer whose cancer had 
progressed after treatment with a non-steroidal aromatase 
inhibitor (32) and approval of panobinostat for the treatment 
of multiple myeloma (33) suggest that a better understanding 
of underlying disease and better stratification of patients may 
improve clinical outcomes for epigenetic therapies.
MG 149 was shown to induce or upregulate the expression 
of several pro-inflammatory chemokines/cytokines including 
CXCL8/IL-8 (Fig. 4). Induction of IL-8 by anti-cancer 
regimens has been seen before in experimental models of 
mesothelioma (34). Levels of IL-8 have also been shown to 
be increased in mesothelioma patients undergoing therapy 
following pleurectomy or extrapleural pneumonectomy 
(EPP) (35), or in patients exposed to intrapleural administra-
tion of tumor necrosis factor-alpha (TNF-α) (36). However, 
elevation of IL-8 levels may not be a reliable marker for 
response to therapy (37), and the induction of pro-inflam-
matory cytokines/chemokine's by MG-149 suggests that as a 
therapy it may elicit cytokine response syndrome (CRS) (38), 
sometimes observed in MPM (39). Indeed, an additional 
potential caveat to the utility of MG 149 as a novel therapeutic 
modality in MPM comes from early research which demon-
strated that IL-8 is pro-angiogenic and acts as an autocrine 
growth factor in MPM (40,41). Furthermore, inhibition of IL-8 
was found to decrease mesothelioma growth both in vitro and 
in vivo (42,43).
In conclusion, KAT5 may represent a novel therapeutic 
target for the treatment of MPM. As its expression has been 
linked to resistance to cisplatin, and current first-line therapy 
of mesothelioma utilize platin based regimens, future studies 
should examine whether KAT5 expression is linked to patient 
outcome, and test the possibility that agents targeting this 
protein could potentially sensitize (or resensitize) patients to 
such regimens.
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